Close Menu

NEW YORK – PerkinElmer said on Thursday morning it has agreed to acquire Oxford Immunotec for about $591 million.

Under the terms of the deal, Waltham, Massachusetts-based PerkinElmer will pay $22 in cash for each outstanding share of Oxford Immunotec's stock, or a 28.3 percent premium to the closing price of the Abingdon, UK-based company's on Jan. 5, the last practicable date prior to the date of the deal. It is also a 53.5 percent premium to the 90-trading-day, volume-weighted average price of Oxford Immunotec's shares for the period from Oct. 8, 2020 to Jan. 5, 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.